Company:  AYTU BIOPHARMA, INC (AYTU)
Form Type:  10-Q
Filing Date:  5/17/2021 
CIK:  0001385818 
Address:  373 INVERNESS PARKWAY
SUITE 206
 
City, State, Zip:  ENGLEWOOD, Colorado 80112 
Telephone:  (720) 437-6580 
Fiscal Year:  06/30 
Last Trade
Last Trade: 
$2.46  
Change: 
-0.10 (-3.91%)  
Trade Time: 
Oct 22  
Market Cap: 
$67.78M
Trade AYTU now with

© 2021  
Description of Business
We are a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address needs in both prescription and consumer health categories. Through our prescription business, and following our recent merger with Neos Therapeutics, Inc. ("Neos"), which closed on March 19, 2021, we market a portfolio of prescription products addressing large markets with a focus on general pediatric conditions, attention deficit/hyperactivity disorder ("ADHD") and insomnia. We also market a portfolio of consumer health products also addressing large categories through our consumer health subsidiary, acquired in February 2020. Our goal is to become a leading specialty pharmaceutical company focused on large prescription and consumer health categories while building a late-stage development pipeline addressing significant medical needs.
Register and access this filing in:     
  FORM 10-Q
    PART I
      FINANCIAL STATEMENTS
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Condensed Consolidated Financial Statements
          INCOME STATEMENT
          INCOME STATEMENT
          BALANCE SHEET
          BALANCE SHEET
          INCOME STATEMENT
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures.
    PART II. OTHER INFORMATION
      Item 1. Legal Proceedings.
      Item 1A. Risk Factors.
      Item 2. Unregistered Sales of Securities and Use of Proceeds.
      Item 3. Defaults Upon Senior Securities.
      Item 4. Mine Safety Disclosures.
      Item 5. Other Information.
      Item 6. Exhibits.
    SIGNATURES
  EXHIBIT 2.4
  EXHIBIT 10.7
  EXHIBIT 10.8
  EXHIBIT 10.9
  EXHIBIT 10.10
  EXHIBIT 10.11
  EXHIBIT 10.12
  EXHIBIT 10.13
  EXHIBIT 10.14
  EXHIBIT 10.15
  EXHIBIT 31.1
    Certification by Chief Executive Officer
  EXHIBIT 31.2
    Certification by Chief Financial Officer
  EXHIBIT 32.1
    CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF ...